How Many Steps a Day You Actually Need, According to New Research
Researchers from the University of Sydney reviewed and analyzed long-term studies conducted between 2014 and 2025 that tracked people's daily steps and various health risks, such as type 2 diabetes, cardiovascular disease, cancer, cognitive function, and mental health, as well as overall mortality.
Compared to walking 2,000 steps a day, the study found that walking 7,000 steps lowered the risk of dementia by 38%, type 2 diabetes by 22%, and cardiovascular disease by 25%. Researchers concluded that the incremental improvement beyond 7,000 steps per day was small, but they acknowledged that some figures may be less accurate than others because they were drawn from only a small number of studies.
The researchers added that even a modest step count can help lower health risks. "For example, 4,000 steps per day compared with 2,000 steps per day was associated with substantial risk reduction, such as a 36% lower risk in all-cause mortality ... the message that every step counts for those who are able should be emphasized as a core public health message, regardless of the specific quantitative target."
According to the study, the goal of 10,000 steps a day is an unofficial target without any clear evidence—it actually started as part of a marketing campaign in Japan. And while that many steps a day can be a good goal for active individuals, the researchers report that 7,000 steps per day "might be a more realistic and achievable target for some."
Read the original article on Martha Stewart
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
19 minutes ago
- Medscape
Medication Non-Adherence Common in Autoimmune Liver Diseases
TOPLINE: Patients with autoimmune liver diseases reported non-adherence to prescribed therapies, with those with autoimmune hepatitis (AIH) reporting the highest rate of non‐adherence. The use of over-the-counter medications and steroids was negatively associated with treatment adherence. METHODOLOGY: Researchers analysed data from a cross-sectional online survey to compare treatment adherence among patients with AIH, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) and identify disease- and patient-related factors affecting compliance. They included 1097 non-transplanted adult patients with autoimmune liver diseases (mean age, 48 years; 79.67% women) from 15 European countries who had AIH (n = 444), PBC (n = 377), or PSC (n = 276) and were taking prescribed pharmacotherapy for disease management. The survey used a questionnaire to collect patient-reported data, including health-related quality of life, somatic symptom burden, anxiety and depression, access to medical care, and prescribed and over-the-counter medications. Patient adherence was classified as a binary variable, with non-adherence defined as skipping medication at least once weekly or a self-initiated dose reduction or discontinuation. TAKEAWAY: Overall, 271 (24.7%) patients reported taking over-the-counter medications, most commonly in patients with PSC (28.3%), followed by those with PBC and AIH (25.2% and 22.1%, respectively). Patients with AIH had the highest rate of non-adherence (47%; 95% CI, 43%-52%), followed by those with PSC (38%; 95% CI, 33%-44%) and PBC (29%; 95% CI, 24%-33%). The use of over-the-counter medications was negatively associated with treatment adherence across all patient groups (odds ratio [OR], 0.50; 95% CI, 0.36-0.68), particularly among patients with AIH (OR, 0.48; 95% CI, 0.29-0.80). Among patients with AIH, treatment with steroids, but not azathioprine, was associated with reduced adherence (OR, 0.52; 95% CI, 0.32-0.84), and among patients with PBC and PSC, treatment with ursodeoxycholic acid was associated with increased adherence (OR, 3.0; 95% CI, 0.66-12.8 and OR, 5.2; 95% CI, 1.4-20.8, respectively). IN PRACTICE: "Our data strongly supports the need for the careful assessment of patient adherence as an essential part of routine medical management. Following the results presented here, physicians should recognize skeptical patient attitude to conservative therapy and focus on the use of alternative medicines by their patients," the authors of the study wrote. SOURCE: This study was led by Ewa Wunsch, Pomeranian Medical University in Szczecin, Szczecin, Poland, and Linda Krause, Institute of Medical Biometry and Epidemiology, University Medical Centre Hamburg-Eppendorf in Hamburg, Germany. It was published online on August 01, 2025, in United European Gastroenterology Journal. LIMITATIONS: A universal tool and measurement criteria for treatment adherence were lacking. The anonymous online format prevented participants from clarifying the questionnaire's content or discussing reasons for low persistence with study providers. The researchers could not draw causal associations or conclusively uncover the causes of patient non-compliance. Additionally, other potential influences on treatment compliance, including economic, social, or healthcare system issues, were not identified in this study. DISCLOSURES: This study was supported by a grant from the Consumers, Health, Agriculture and Food Executive Agency. The authors reported no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
19 minutes ago
- Medscape
Does Getting Fit Guard Against Colorectal Cancer?
Evidence continues to mount that building cardiovascular fitness can help lower an individual's risk for colorectal cancer (CRC). The latest study — a sweeping analysis of 643,583 individuals, with more than 8000 cases of CRC and 10 years follow-up — found a consistent, inverse, and graded association between cardiorespiratory fitness (CRF) and the risk for the development of CRC — a benefit similar for men and women and across races. CRC risk was 9% lower for each 1-metabolic equivalent (MET) task increase in CRF, objectively measured by an exercise treadmill test. When assessed across CRF categories, there was a progressive decline in CRC risk with higher CRF, Aamir Ali, MD, and colleagues with Veterans Affairs Medical Center, Washington, DC, found. Compared with the least fit individuals (METs, 4.8), the CRC risk was 14% lower in those falling in the low-fit CRF category (METs, 7.3), 27% lower for moderately fit people (METs, 8.6), 41% lower for fit individuals (METs, 10.5), and 57% lower for high-fit individuals (METs, 13.6). Moderate CRF is attainable by most middle-aged and older individuals, by engaging in moderate-intensity physical activity such as brisk walking, which aligns with current national guidelines, the authors said. The study was published online on July 28 in Mayo Clinic Proceedings. The results dovetail with earlier work. For example, in the Cooper Center Longitudinal Study, men with high mid-life CRF had a 44% lower risk for CRC and a 32% lower risk of dying from cancer later in life men with low CRF. A recent meta-analysis for the World Cancer Research Fund estimated a 16% lower risk for colon cancer in people with the highest levels of recreational physical activity relative to those with the lowest levels. A recent UK Biobank analysis using accelerometers linked higher daily movement to a 26% reduction in risk across multiple cancers, including bowel cancer. Taken together, the data suggest that 'the more you exercise, the better your overall health is going to be — not just your cardiac fitness but also your overall risk of cancer,' Joel Saltzman, MD, medical oncologist at Cleveland Clinic Taussig Cancer Center, Cleveland, noted in an interview with Medscape Medical News . Can You Outrun CRC Risk? In the US, CRC is the second leading cause of cancer mortality, accounting for 51,896 deaths in 2019. The economic burden of CRC in the US is significant, topping $24 billion annually. And while the incidence of colon cancer has decreased in older individuals during the past 3 decades, the incidence in younger adults has nearly doubled during the same period, 'underscoring the limitations of screening programs and the critical need for risk factor modification,' Ali and colleagues wrote. 'There is good evidence that exercise and healthy lifestyle/diet have significant benefit overall and as well for some potential risk reduction for colon cancer,' David Johnson, MD, professor of medicine and chief of gastroenterology, Eastern Virginia Medical School in Norfolk, Virginia, told Medscape Medical News. 'There are clearly suggestions of why this makes sense via the beneficial effects of exercise and physical activity in CRC pathways including but not limited to regulation of inflammation and aberrant cell growth/cancer pathways,' Johnson said. He emphasized, however, that exercise and lifestyle are not the best way to prevent CRC. 'Appropriate screening, in particular by colonoscopy (by skilled physicians who meet high-quality performance national benchmarks) to detect and remove precancerous polyps, is the best approach for prevention,' Johnson said. 'At this point — albeit exercise is potentially helpful and a great general recommendation — my most current advice as an expert in the field, is that you cannot outrun CRC risk,' Johnson said. Can You Outrun CRC Recurrence? Prevention aside, the data thus far are even more supportive of risk reduction for patients who have had CRC and are targeting reduction of recurrence, Johnson said. Perhaps the most compelling study was recently published in The New England Journal of Medicine. The CHALLENGE trial enrolled patients with resected stage II or III colon cancer who had completed their adjuvant chemotherapy. Patients with recurrences within a year of diagnosis were excluded, as they were more likely to have highly aggressive, biologically active disease. Participants were randomized to receive healthcare education materials alone or in conjunction with a structured exercise program over a 3-year follow-up period. The focus of the exercise intervention was increasing recreational aerobic activity over baseline by at least 10 METs — essentially the equivalent of adding about 45-60 minutes of brisk walking or 25-30 minutes of jogging three to four times a week. At a median follow-up of nearly 8 years, exercise reduced the relative risk for disease recurrence, new primary cancer, or death by 28% ( P = .02). 'This benefit persisted — and even strengthened — over time, with disease-free survival increasing by 6.4 and 7.1 percentage points at 5 and 8 years, respectively,' Johnson noted in a Medscape commentary. The CHALLENGE results are 'very compelling,' Bishal Gyawali, MD, PhD, associate professor of oncology at Queen's University, Kingston, Ontario, Canada, noted in a separate Medscape commentary. 'If you compare these results with results from other trials, you'll see that this is a no-brainer. If this were a drug, you would want to use it today,' Gyawali said. Saltzman told Medscape Medical News patients often ask him what they can do to help prevent their cancer from coming back. 'I would sort of say, 'Well, eat a healthy diet and exercise,' but I didn't have a lot of good evidence to support it.' The CHALLENGE study provides 'the proof in the pudding.' With these strong data, 'it almost feels like I should be able to write a prescription for my patient to join an exercise program and that their insurance should cover it,' Saltzman said.
Medscape
19 minutes ago
- Medscape
ED Use Before Cancer Tied to Higher Mortality
TOPLINE: In a matched cohort study of 410,120 patients with cancer, emergency department (ED) visits within 90 days before diagnosis were associated with a significantly increased risk for mortality, and the elevated risk persisted through 7 years of follow-up. METHODOLOGY: Researchers conducted a retrospective study of 410,120 adults diagnosed with cancer between 2014 and 2021 in Ontario, Canada, with follow-up until death, 7 years, or March 31, 2024. A total of 205,060 patients who had ED visits in the 90 days before cancer diagnosis were matched 1:1 with patients without such visits, based on sex, year of diagnosis, and propensity scores. The primary outcome was all-cause mortality. TAKEAWAY: Overall mortality was 61.7% in patients with ED use vs 37.8% in those without ED use; the risk remained consistently higher among patients with ED use across all timepoints. The elevated risk for mortality among patients with ED use was highest at 30 days (hazard ratio [HR], 4.49; 95% CI, 4.40-4.58) and remained significant over 7 years (HR at 7 years, 1.05; 95% CI, 1.01-1.09). Patients hospitalized at the ED visit had a higher risk for mortality at all timepoints (HR at 30 days, 5.83; 95% CI, 5.69-5.99; HR at 7 years, 1.30; 95% CI, 1.23-1.37). Additionally, discharged patients had a higher risk for mortality up to 3 years (HR at 30 days, 2.68; 95% CI, 2.59-2.77; HR at 3 years, 1.38; 95% CI, 1.34-1.41; HR at 7 years, 1.03; 95% CI, 0.98-1.10), but the association was not significant for follow-up beyond 3 years. IN PRACTICE: Higher risk for mortality among patients presenting to the ED prior to cancer diagnosis emphasizes the need for "established systems of care to ensure timely cancer workup for patients with suspected cancer in the ED" and "health care system improvements to enhance early cancer detection and management, thereby reducing the reliance on emergency care for initial cancer presentations," the study authors wrote. SOURCE: The study was led by Keerat Grewal, MD, MSc, Schwartz/Reisman Emergency Medicine Institute, Sinai Health, Toronto, Ontario, Canada, and was published online on July 22, 2025, in JAMA Network Open. LIMITATIONS: Unrelated ED visits may have been included. The observational design limited causal inference. The cancer stage at diagnosis and race and ethnicity were not accounted for. DISCLOSURES: The study was supported by Canadian Institutes of Health Research and ICES, which is funded by the Ontario Ministry of Health and the Ministry of Long-Term Care. One author reported receiving a salary from ICES outside the submitted work. Several authors reported receiving research grants or personal fees or serving as experts for various organizations.
